SI-BONE Inc. (SIBN) Misses Q3 EPS by 2c, Slight Beat on Revenues; Offers FY18 Revenue Outlook

SI-BONE Inc. (NASDAQ: SIBN) reported Q3 EPS of ($0.30), $0.02 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $13.38 million versus the consensus estimate of $13.32 million.

“Our third quarter accomplishments reflect the ongoing strength of our business,” said Jeffrey Dunn, President, Chief Executive Officer, and Chairman. “We are pleased to see continued momentum in exclusive reimbursement policies and growing clinical evidence, which further validates our position as the market leader for providing minimally invasive surgical products for the sacroiliac joint.”

“In addition, we are pleased with the successful completion of our IPO and are grateful for the support of the participating investors,” continued Mr. Dunn. “The proceeds from this offering will enable us to continue to expand our commercial footprint in the United States and elsewhere, and better target the hundreds of thousands of patients suffering from low back pain caused by SI joint dysfunction.”

GUIDANCE:

SI-BONE Inc. sees FY2018 revenue of $55-55.4 million, versus the consensus of $55.14 million.

For earnings history and earnings-related data on SI-BONE Inc. (SIBN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79